These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38663057)

  • 1. Cost-Effectiveness Analysis of Pharmacological Treatment for Adult Kidney Transplant Recipients in Colombia.
    Sanmartin D; Tamayo C; Orozco LE; Ordóñez A; Huertas J; Ávila D; Echeverry J; Caicedo M; García P
    Value Health Reg Issues; 2024 Jul; 42():100983. PubMed ID: 38663057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
    Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
    Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
    Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Tacrolimus Compared With Cyclosporine for Immunosuppression Therapy in Patients Who Underwent Heart Transplant in Colombia.
    Tamayo C; Huertas J; Sanmartin D; Ordóñez A; Ávila D; Mendoza F; Orozco E
    Value Health Reg Issues; 2023 Nov; 38():61-68. PubMed ID: 37573854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of modern mTOR inhibitor based immunosuppression compared to the standard of care after renal transplantation in Germany.
    Jürgensen JS; Ikenberg R; Greiner RA; Hösel V
    Eur J Health Econ; 2015 May; 16(4):377-90. PubMed ID: 24728542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
    Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
    Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
    Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
    JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of new immunosuppressive regimens on cost of renal transplant maintenance immunosuppression.
    Gentil MA; González-Roncero F; Cantarell C; López M; Marco J
    Transplant Proc; 2005 Apr; 37(3):1441-2. PubMed ID: 15866631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive agents in adult kidney transplantation in the National Health Service: a model-based economic evaluation.
    Snowsill TM; Moore J; Mujica Mota RE; Peters JL; Jones-Hughes TL; Huxley NJ; Coelho HF; Haasova M; Cooper C; Lowe JA; Varley-Campbell JL; Crathorne L; Allwood MJ; Anderson R
    Nephrol Dial Transplant; 2017 Jul; 32(7):1251-1259. PubMed ID: 28873970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK.
    McEwan P; Dixon S; Baboolal K; Conway P; Currie CJ
    Pharmacoeconomics; 2006; 24(1):67-79. PubMed ID: 16445304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus and azathioprine versus cyclosporine and mycophenolate mofetil after lung transplantation: a retrospective cohort study.
    Celik MR; Lederer DJ; Wilt J; Eser D; Bacchetta M; D'Ovidio F; Sonett JR; Arcasoy SM
    J Heart Lung Transplant; 2009 Jul; 28(7):697-703. PubMed ID: 19560698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation.
    Baker GM; Martin JE; Jang R; Schroeder TJ; Armitstead JA; Myre S; First MR
    Transplant Proc; 1998 Dec; 30(8):4082-4. PubMed ID: 9865304
    [No Abstract]   [Full Text] [Related]  

  • 20. Mycophenolate mofetil--is it worth the cost? The in-favor opinion.
    Seikaly MG
    Pediatr Transplant; 1999 Feb; 3(1):79-82. PubMed ID: 10359036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.